M&A boost as Johnson & Johnson bids for Actelion

By Silas Brown
26 Jan 2017

Johnson & Johnson has offered Actelion a 23% premium on its shares in a $30bn all-cash bid, in what would be the largest European pharmaceuticals transaction in a decade. And with M&A activity strong during January, investment grade loan bankers are feeling more optimistic.

After talks that began in December, Johnson & Johnson on Thursday offered Actelion shareholders $280 a share in the all-cash offer. If accepted, the US company will start the tender offer by mid-February.

A bridge facility to back the buyout ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.